Nu Skin is looking for new avenues to find anti-aging solutions. The company will acquire Nox Technologies, Inc., a biotechnology and biodiagnostic company based in Malvern, PA for $12.5 million. The agreement includes the acquisition of technology and patents, including previously licensed technology already utilized in connection with Nu Skin’s anti-aging research efforts.
“The acquisition of Nox Technologies demonstrates our ongoing commitment to scientific innovation and provides us with additional tools to target the sources of aging,” said chief scientific officer Joe Chang, Ph.D. “Furthermore, we believe the acquisition will enhance our long-term pipeline of scientifically validated anti-aging solutions for health, beauty and wellness.”
Nox Technologies provides Nu Skin scientists with a deeper understanding of the aging process and supports the company’s ability to understand important sources of aging. arNox, an age-related protein identified by Nox Technologies, is found on the cell surface and is capable of superoxide generation, a relevant aspect of the aging process.
“This merger is the culmination of many years of working with Nu Skin researchers on our arNox technology. Nox Technologies’ translation of the basic science around arNox paved the way for this unique technology to be incorporated into Nu Skin’s successful anti-aging research and development efforts,” said Thomas B. Shelton, CEO, Nox Technologies.
The acquisition is subject to customary closing conditions. Closing is expected by the end of the year.